SABS SAB Biotherapeutics: Rasio rega marang prakiraan pendapatan
SAB Biotherapeutics (SABS) efficiency is based on partnerships with external laboratories while maintaining control over bio-assets. The GURU.Markets service features a line chart where the forward revenue multiple 1668.60 records a new level. This confirms the platform's flexibility in creating antibodies against diabetes, although financial stability remains vulnerable due to high production costs and potential FDA delays in final testing.
Rincian metrik komprehensif lan analitis SAB Biotherapeutics Inc (SABS)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas SAB Biotherapeutics|SABS - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal SAB Biotherapeutics|SABS - Utang perusahaan|Utang-utang marang kapitalisasi buku SAB Biotherapeutics Inc|SABS - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan SAB Biotherapeutics|Indikator likuiditas cepet sabbiotherapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
SABS - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep SAB Biotherapeutics|SABS - Nilai perusahaan marang bathi resik|Pangali Forward P/E SAB Biotherapeutics, Inc|SABS - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan SAB Biotherapeutics Inc|SABS - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) SAB Biotherapeutics|SABS - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan sabbiotherapeutics.com|SABS - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep SAB Biotherapeutics
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:SAB Biotherapeutics, Inc. SABS
The forward P/S ratio assesses the market value of an asset relative to projected revenue, allowing investors to determine the extent of the premium paid for expected sales growth. By analyzing the projected P/S multiple on the GURU.Markets platform, an investor can diagnose speculative overheating for SAB Biotherapeutics (SABS), which is critical for an antibody developer whose capitalization depends directly on clinical trial outcomes and FDA approvals.
Analisis perusahaan pesaing
Multiplikator Forward P/S ARGX (argenx)|BioNTech Inc. (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABVX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake ADMA Corp ADMA|PTGX: Multiplikator Forward P/S|immunovant.com (IMVT) - Multiplikator Forward P/S|KNSA (Kiniksa) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan GRFS|Multiplikator forward rega marang pendapatan ADPT (Adaptive Biotechnologies Corp)|CLDX (Celldex Corp) - Rega forward marang dodolan|Multiplikator Forward P/S AUPH (Aurinia Pharmaceuticals)|biocryst.com - Rasio rega marang prakiraan pendapatan|Vera Therapeutics - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Dianthus Therapeutics Inc DNTH|Pharvaris Corp (PHVS) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep AbCellera Corp (ABCL)|Multiplikator forward rega marang pendapatan TRML|PGEN (precigen.com) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S PHAR|NKTR (Nektar Therapeutics Inc) - Rega forward marang dodolan|Multiplikator Forward P/S UPB (Upstream Bio Corp)|Zenas Corp (ZBIO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|IMNM - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan GOSS (gossamerbio.com)|KALV: Multiplikator Forward P/S|Septerna, Inc. (SEPN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals Inc|Savara Pharma - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S RIGL|ANAB - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Astria Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S enGene Holdings Inc ENGN|RAPT: Multiplikator forward rega marang pendapatan|Aerovate Therapeutics Inc - Rasio rega marang pendapatan sing dikarepake|ACRS: Multiplikator Forward P/S|KYTX - Rasio kapitalisasi marang dodolan sing dikarepake|TLSA (Tiziana Life Sciences Ltd) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Cabaletta Bio Inc. (CABA)|Rasio rega marang prakiraan pendapatan Ventyx Bio (VTYX)|Rasio kapitalisasi marang dodolan sing dikarepake Theratechnologies, Inc|Rasio rega marang prakiraan pendapatan Avalo Therapeutics, Inc AVTX|Rasio kapitalisasi marang dodolan sing dikarepake eledon.com (ELDN)|Agenus Inc. - Multiplikator Forward P/S|CLYM - Multiplikator Forward P/S|ZURA: Multiplikator Forward P/S|ATYR (aTyr Pharmaceuticals) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Adagene Inc|Ikena Oncology, Inc. (IMA) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Shattuck Labs, Inc. (STTK)|EQ: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CNTB (Connect Biopharma Holdings Limited)|Rega forward marang dodolan IMUX|Atara Biotherapeutics Inc - Multiplikator Forward P/S|IFRX - Multiplikator Forward P/S|X4 Pharmaceuticals, Inc. (XFOR) - Rasio rega marang prakiraan pendapatan|Adicet Bio, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Celularity Inc|Multiplikator forward rega marang pendapatan INmune Bio Corporation (INMB)|Multiplikator Forward P/S BRNS|Multiplikator Forward P/S kezarlifesciences.com (KZR)|Akari Therapeutics Plc - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ENLV|Q32 Bio Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan ibioinc.com|Rasio rega marang prakiraan pendapatan Carisma Therapeutics Inc|Multiplikator forward rega marang pendapatan XTL Biopharmaceuticals Ltd (XTLB)|Multiplikator forward rega marang pendapatan BOLT (Bolt Biotherapeutics)|Multiplikator Forward P/S hcwbiologics.com (HCWB)|Rasio rega marang prakiraan pendapatan Aptevo Therapeutics Inc. APVO|AIM: Kapitalisasi marang prakiraan pendapatan|Aditxt Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GRI Bio Inc|XORTX (XRTX) - Rasio rega marang prakiraan pendapatan|HIND - Rasio kapitalisasi marang dodolan sing dikarepake|REVB (Revelation Biosciences) - Multiplikator Forward P/S|Multiplikator Forward P/S indaptusrx.com|Multiplikator Forward P/S SCNI|Rasio rega marang prakiraan pendapatan CALI (calcimedica.com)|Affimed N.V. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ALLK|HOOKIPA - Multiplikator Forward P/S|IGMS: Rasio rega marang prakiraan pendapatan|ITOS: Multiplikator Forward P/S|OCEA - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Third Harmonic Bio Inc THRD
